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CANINE COGNITIVE DISFUNCTION SYNDROME
 AbstractAlzheimer’s disease (AD) is a devastating neurodegenerative disorder that usu-ally affects individuals of an older age. Aged dogs spontaneously develop many fea-tures of human aging and Alzheimer’s disease (AD) including cognitive decline and neuropathology. AD is accompanied by progressive dementia and the accumulation 
of senile plaues and neurofibrillary tangles. Plaues contain a toic peptide called 
beta-amyloid (AȾ) which is produced from the longer AȾ precursor protein (APP) by 
seuential proteolytic cleavage by beta-secretase and gamma-secretase. Neurofibri-
llary tangles are composed of hyperphosphorylated tau protein that fills the cytopla-
sm of neurons, leading to degeneration.  Moreover it is found that AȾ deposition may 
lead to oidative damage or vice versa, oidative damage may lead to AȾ. Canines are useful for aging research. The canine model has a rich literature in psychological and neurobiological research, dating back to the 1800s. Dogs also offer additional predi-
ctive validity when translating results to human clinical trials, as they absorb phar-
maceuticals with similar if not identical pharmacokinetics. There are also cognitive 
testing procedures for canines that were developed to assess cognitive function in va-rious domains and corresponding brain localization in dogs. Measures of canine fun-
ction can also be assessed in a clinical setting. Clinical measures have been developed 
consisting of pet dog owner based evaluation of dog behavioral changes similar to 
those used in human clinical evaluations, such as the mini mental state eam (MMSE). The canine model has numerous advantages, so the aged dog may capture key featu-res of human aging, making them particularly useful for studies of therapeutics that can be translated into human clinical trials. 
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Pregledni rad
SINDROM KOGNITIVNE DISFUNKCIJE KOD PASA
ā
Alchajmerova bolest (AB) je devastirajući neurodegenerativni poremećaj koji naj-
češće poga¯a osobe starije dobi. Stariji psi mogu spontano razviti mnoge karakteri-
stike ljudskog starenja i Alchajmerove bolesti (AB), uključujući pad kognitivnih funk-
cija i neuropatologiju. AB prati progresivna demencija i akumulacija senilnih plakova 
i neurofibrilarno zapetljavanje. Plakovi sadrāe toksični peptid ‒  beta-amiloid (AȾ) 
koji se proizvodi sekvencijacijom iz više AB prekursorskih proteina (APP) uz aktiv-
nost proteolitičkih beta-sekretaza i gama-sekretaza. Neurofibrilarna klupka se sastoji 
od hiperfosforilisanih „tau“ proteina koji ispunjavaju citoplazmu neurona, što dovodi 
do degeneracije. Osim toga je utvr¯eno da AB taloāenja mogu dovesti do oksidativnog 
oštećenja ili obrnuto. Psi su korisni za istraāivanje starenja. Upotreba pasa kao mode-
la ima bogatu istoriju u psihološkim i neurobiološkim istraāivanjima, koja datiraju iz 
1800. godine. Psi tako¯e nude dodatne informacije prilikom kliničkih ispitivanja na 
ljudima, jer oni apsorbuju lijekove i imaju sličnu ako ne i identičnu farmakokinetiku. 
Tu su i kognitivne procedure za testiranje pasa koje su razvijene za procjenu kogni-
tivne funkcije u različitim oblastima i odgovarajućih lokalizacija u mozgu pasa. Mjere 
funkcije mozga pasa mogu se procijeniti u kliničkom okruāenju. Razvijene su kliničke 
mjere koje se sastoje od vrednovanja baziranih na promjenama ponašanja pasa slič-
nim onima koje se koriste u kliničkim studijama ljudi, kao što su to „mini mental state 
eam“ (MMSE). U modelu psa postoje brojne prednosti, tako da se starenjem kod psa 
mogu uočiti ključne karakteristike ljudskog starenja, što ih čini posebno korisnim za 
studije terapije koje se mogu koristiti u kliničkim ispitivanjima na ljudima.
««ǣAlchajmerova bolest (AB), beta-amiloid (Aβ), kognitivni disfunkcija 
sindrom kod pasa, promjene ponašanja, pas.
 INTRODUCTION / UVOD
Dementia is defined as a clinical syn-drome characterized by symptoms and signs such as changes in memory, orien-tation, behavior, language and other co-gnitive functions, and impairment in acti-vities of daily living. Alzheimer’s dise-
ase (AD), which is named after the Ger-
man psychiatrist Alois Alzheimer, who 
first described this disorder in 1907, is the most common cause of dementia, ac-
counting for up to 75 Ψ of all dementia cases. AD is a progressive neurodegene-
rative disorder Canine Cognitive Dysfun-
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ction (CCD) is a term that was introduced to describe geriatric behavioral changes, not solely attributable to a general medi-
cal condition (Overall, 2000, Ruehl WW, 
1998) such as infection, organ failure or 
neoplasm. Senile dementia and senile degeneration of the brain are terms also used in the literature. 
EPIDEMIOLOGY / 
EPIDEMIOLOGIJAIt is estimated that about 46.8 million 
people worldwide are living with demen-
tia in 2015. This number will almost dou-
ble every 20 years, reaching 7Ͷ.7 million 
in 2030 and 131.5 million in 2050. 
A recent retrospective(Hart BL, 1997, 
Neilson et al., 2001)  study eamined 180 
dogs (83 castrated males and 97 spayed females)  representing  3  age  groups, na-
mely, dogs aged 11-12, 13-1Ͷ, and 15-1͸ 
years old. Mild cognitive impairment was 
defined  as  signs  in  only  one category 
whereas  severe  cognitive  impairment 
was described as signs in 2 or more ca-tegories. The percentage of 11  to 12 ye-
ar-old dogs with minor  impairment was 
17.5Ψ  and  severe impairment was  10Ψ 
(total  number  of  dogs affected 27.5Ψ).
The percentage of 15 to 1͸ year- old dogs 
were 32Ψ and 35Ψ for mild and severe impairment respectively (total number of 
dogs affected  ͸7Ψ). Data were also colle-cted to monitor progression of agerelated behavioral changes in old dogs over a pe-riod of 6-18 months. The increase in im-
pairment was significant within all cate-gories.  A large cross-sectional epidemiolo-
gical study of older dogs (Salvin et al., 
2010) aimed to estimate the prevalence 
of CCD amongst community based dogs 
(mean age 11.͸7 yearsǢ range 8Ȃ19.75) and to determine the rate of veterinary diagnosis amongst affected dogs. An 84-
item uestionnaire was used to obtain in-
formation across si behavioral domains. 
Of the eligible survey responses obtained 
(n α 957) a randomly selected one-half 
(n α Ͷ97) was used for this study. Using a 
provisional diagnosis based on 27 signi-
ficant behavioral items, the prevalence 
rate of CCD was estimated to be 1Ͷ.2Ψ. 
This was in contrast with only 1.9Ψ dia-
gnosed with CCD by a veterinarian. The-
re was an eponential increase in preva-
lence of CCD with age (R2 α 0.9Ͷ35), but prevalence did not differ by breed size 
or between longevity groups. The preva-
lence rate of CCD reported in this study 
is consistent with previous findings, and further supports the contention that the 
majority of these dogs do not receive a formal diagnosis. 
ALZHEIMER DISEASE / 
ALCHAJMEROVA BOLEST
PATHOPHYSIOLOGY / 
PATOFIZIOLOGIJA
Just as canines can ehibit cognitive 
decline with age similar to aging humans 
and patients with AD, several human-ty-pe neuropathologies have been repor-
ted in dogs (Cotman and Head, 2008). The canine model has long been sugge-
sted as an ecellent model of AȾ patho-
genesis (Wisniewski et al., 1990). Dogs normally share environmental conditi-
ons with humans and present a sophisti-
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cated repertoire of comple cognitive be-haviors. Furthermore, the brain in aged 
dogs shows many pathological changes common to humans and the neuropat-
hological patterns are significantly asso-
ciated with cognitive decline (Head et al., 
2000b). Several changes observed in the 
aged canine brain are associated with co-gnition. 
Individuals with AD show significant cortical and hippocampal atrophy rela-tive to non-demented age matched con-
trols (Alavi et al., 1993, Raz et al., 1998) 
and losses in brain volume correlate with 
cognitive decline (Du et al., 2005, Ezekiel 
et al., 200Ͷ). Similar events are seen in 
aged canines. On cross sectional MR ima-
ging, aging canines show increased cor-
tical atrophy and ventricular widening 
(Gonzalez-Soriano et al., 2001, Kimotsu-
ki et al., 2005, Su et al., 1998). Ventricu-
lar widening over time was observed by 
MRI in a 3-year longitudinal study (Su et 
al., 2005). Canine cortical atrophy occurs 
earliest in the prefrontal corte and later 
with age in the hippocampus (Tapp et al., 
200Ͷ). As with humans, the more eten-
sive the cortical/hippocampal atrophy seen in aged canines the more pronoun-
ced the cognitive deficits (Rofina et al., 
200͸). J. E. Rofina et. al. (Rofina et al., 
200͸)  made a study, in which cognitive 
performance was correlated with brain 
pathology for 30 dogs of varying ages. Wi-
thin these animals, two age-matched gro-
ups of old dogs with and without behavi-
oral changes were compared. The beha-
vioral changes were analyzed and scored 
with uestionnaires and necropsy was performed to rule out any other cause for 
changed behavior. Measurements, (im-
muno)-histochemical staining and fluo-
rescence microscopy were used to detect 
corte atrophy, amyloid, rest-products of 
oidative damage, demyelination and ac-cumulations of macrophages in the bra-
ins of these dogs. Spearman rank correla-
tion coefficients (r) were calculated and 
adjusted according to Bonferonni. In the 
whole group (young to very old dogs), 
the age of the animal showed a signifi-
cant correlation with various behavioral 
changes (r α 0.7 to 0.9, P δ 0.01). The de-
mentia score correlated significantly (r α 
0.͸ to 0.8, P δ 0.01) with all the brain le-
sions studied, ecept one, i.e. demyelina-
tion (r α Ϋ0.Ͷ, Pα0.05). These results su-ggest that a questionnaire can be used to diagnose Alzheimerlike changes in cani-
ne practice. Oidative damage on a cellu-lar and a nuclear level plays an important role in behavior changes. Neuronal loss occurs in human bra-
in aging and could eplain the brain vo-
lume loss seen in brain imaging (Simic et 
al., 1997). With normal brain aging, neu-
ronal loss is only seen in the hilus (West 
et al., 199Ͷ), while neuronal loss is much 
more widespread in individuals with AD. 
Moreover, in individuals with AD the-
re is neuronal loss in the CA1, CA2, CAͶ, 
and subiculum of the hippocampus (Bo-
binski et al., 1997, West et al., 2000). In aged beagles, the hilus of the dentate 
gyrus showed fewer neurons compared 
to younger dogs. Beagles with fewer neu-
rons in the hilus made significantly more 
errors when performing the size discri-
mination task (Siwak-Tapp et al., 2008). 
Moreover, a loss of Purkinje cells in cani-
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nes correlate with data acuired by ue-
stionnaires uantifying behavioral defi-
cits. However, neuronal loss may not ac-count for all of the brain atrophy obser-
ved by MR as the loss of neuronal den-
dritic spines occurs with AD (Knobloch 
and Mansuy, 2008)  but to our knowled-ge, there are currently no studies publis-
hed evaluating similar changes with age in dogs. 
The brain is also able to produce new neurons despite the fact that neuronal 
loss may occur with aging. The hippo-
campus, for eample, grows new neurons in the sub-granular layer (Eriksson et al., 
1998). Neurogenesis has been studied in 
aged beagles using BrdU and double cor-
tin protein staining methods. Siwak-Tapp 
et al.(Siwak-Tapp et al., 2007) measured 
neurogenesis in aged beagles using BrdU and found that animals over the age of 13 
eperienced a significant loss of neuro-
genesis. Fewer newer BrdU positive neu-
rons were associated with poorer cogni-tive function in learning and memory and learning ability. Neuronal dysfunction could result in abnormal production of critical neu-rotransmitters in the brain. Neurotran-
smitter deficits have not been thoroughly 
eplored in canines. In humans, decrea-
ses in specific neurotransmitter systems 
are associated with aging and AD (Mel-
tzer et al., 1998, Rissman et al., 2007). 
Dogs with AȾ accumulation in the gyrus 
proreus possess fewer serotonergic ne-
urons (Bernedo et al., 2009). A decrease in receptor binding of serotonin is seen 
with age in dogs over 8 years of age (Pe-remans et al., 2002). 
Animals with high levels of AȾ in the 
prefrontal corte eperience a loss of no-radrenergic neurons in the locus cerule-
us, which is also associated with cogniti-ve dysfunction (Insua et al., 2010). Acetyl-cholinesterase density is reduced in gra-
nule cells of the cerebellum with age (Pu-
gliese et al., 2007). Aged canines epe-rience a loss of gamma-aminobutyric acid interneurons in the prefrontal cor-
te (Pugliese et al., 200Ͷ), as well as the 
CA1 and dentate gyrus of the hippocam-pus. Additionally, a loss of glutamic acid 
decarboylase neurons in CA1 of the hi-ppocampus is seen in aged canines over 
10 years of age (Hwang et al., 2008). The pathogenic mechanisms underlying neu-ronal dysfunction, neurotransmitter los-ses and death may include, e.g., the depo-
sition of AȾ, cerebrovascular dysfunction, 
or oidative damage. AD is accompanied by progressive de-mentia and the accumulation of senile 
plaues and neurofibrillary tangles (Mi-
rra, 1997). Plaues contain a toic peptide 
called beta-amyloid (AȾ), which is produ-
ced from the longer AȾ precursor prote-
in (APP) by seuential proteolytic cleava-ge by beta-secretase and gamma-secreta-
se (Selkoe, 199Ͷ). AȾ forms either etra-cellular deposits or soluble assembly sta-
tes (oligomers)(Haass and Selkoe, 2007, 
Walsh et al., 2002). Neurofibrillary tan-gles are composed of hyperphosphoryla-
ted tau protein that fills the cytoplasm of neurons, leading to degeneration (Iqbal 
and Grundke-Ibal, 2008). As with most natural animal models of AD, dogs deve-
lop AȾ pathology and some evidence for 
tau abnormalities but not full blown ne-
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urofibrillary tangles. C.-H. Yu et. al. (Yu et al., 2011)  investigated tau phosphoryla-tion of neurons and astrocytes in the bra-
in of aged dogs with progressive cogni-
tive impairment. Changes in the brain 
of aged dogs with cognitive dysfunction 
were compared with those in the brain of 
patients with AD of Braak stage V. Immu-nohistochemically, Ab deposition, phosp-
horylated tau Ser39͸ (p-tau Ser39͸) and 
ubiuitin were observed in the parietal 
corte and hippocampus of aged dogs 
with cognitive dysfunction. Astrocytes 
with epression of p-tau Ser39͸ and neu-
rons with co-localization of p-tau Ser39͸ 
and ubiuitin were observed. Epressi-
on of p-tau Ser39͸ and accumulation of 
ubiuitin were significantly increased in 
the parietal corte and dorsal part of the hippocampus of the brain of aged dogs 
when compared with epression of these molecules in human AD. 
Beta-amyloid (AȾ) is derived from a longer precursor protein, the amylo-
id precursor protein (APP). The APP 
seuence of Canis familiaris has 98Ψ ho-
mology with human APP2 and an iden-tical amino acid sequence (Johnstone et 
al., 1991). Additionally, dog AȾ peptides may undergo the same posttranslational 
modifications as in humans (Azizeh et al., 2000). These similarities make canines 
a viable aging model without the need 
for genetic modification or overepres-
sion of mutant human proteins(Selkoe 
et al., 1987). Geun-Shik Lee et. al. (Lee et al., 2014)  generated transgenic canines 
that overepressed the human amyloid 
precursor protein (APP) gene containing 
well-characterized familial Alzheimerǯs 
disease (AD) mutations. Ȯhey success-
fully obtained five out of si live puppies 
by somatic cell nuclear transfer (SCNT). 
This was confirmed by observing the 
epression of green fluorescence prote-in in the body as a visual transgenic mar-
ker and the overepression of the muta-
ted APP gene in the brain. The transge-nic canines developed AD-like symptoms, such as enlarged ventricles, an atrophied 
hippocampus, and Ⱦ-amyloid plaues in the brain. Thus, the transgenic canines 
we created can serve as a novel animal model for studying human AD. 
In another study, Giaccone et.al.(Giac-
cone et al., 1990)  investigated the brains 
of 7 dogs aged ͸ to 18 years  histochemi-cally and immunohistochemically at the light- and electron microscopy levels for 
preamyloid deposits and amyloid fibrils to verify the hypothesis that the accu-mulation of cleavage products of amylo-id precursor protein is related not only to Alzheimer’s disease but also to the nor-
mal aging of the brain. Preamyloid depo-
sits were detected in the neuropil of the 
cerebral corte and neostriatum, where-
as amyloid fibrils were found in the walls of parenchimal and leptomeningeal ves-sels. The densities of preamyloid deposits in the neuropil and of deposits of amylo-
id fibrils in the vessel walls were higher in the brains of the most aged dogs. The-
se findings suggest that aging of the cani-ne brain is characterized by an accumu-lation of intermediate cleavage products of the amyloid precursor protein in both 
the neuropil and the vessel walls, and by processing of these products to amyloid 
fibrils in the vessel walls. 
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The AȾ present in canines is ultra-
structurally fibrillar and, though more compact deposits may form, it generally aggregates into diffuse plaques (Torp et 
al., 2000a, Torp et al., 2000b, Giaccone 
et al., 1990). This type of AȾ depositi-on most resembles early AD pathology(-
Cotman and Head, 2008). In canines, the 
accumulation of AȾ begins in the prefron-
tal corte (approimately 8 years at age 
of onset) and continues to develop with increasing age to include other regions such as the temporal and occipital cor-
te(Head et al., 2000a). Schmidt F et. al. 
(Schmidt et al., 2015)  eamined the bra-ins of 24 dogs from various breeds. The 
frontal corte, hippocampus, and entor-
hinal corte were investigated. Deposits 
of Ⱦ-amyloid (AȾ) and tau were analy-
zed phenotypically and uantified stere-ologically. In all dogs aged 10 years or ol-
der, plaues containing pyroglutamyl AȾ 
and AȾ8-17 were detected. Within the 
ventral hippocampus, significantly more 
pyroglutamyl AȾ plaues were deposited in small and medium dogs than in large 
dogs. Hyperphosphorylated tau with for-
mation of neurofibrillary tangles was ob-
served in 3 animals aged 13 to 15 years. 
This study provides the first investigation 
of pyroglutamyl AȾ in comparison with 
total AȾ (as shown by AȾ8-17 immunore-activity) in dogs of different breeds, sizes, and ages. The results indicate that canine cognitive dysfunction syndrome is relati-vely common among aged canines, the-reby emphasizing the relevance of such populations to translational AD resear-
ch.  AȾ peptide can also be measured in 
the cerebrospinal fluid (CSF) of dogs(Sa-
rasa et al., 2013). Measuring CSF AȾ as 
a ratio of AȾ Ͷ2/AȾ Ͷ0 is a good predi-
ctor of AȾ in the brain in dogs (Head et 
al., 2010). While brain AȾ increases with 
age, CSF AȾ decreases with age reflecting 
the hypothesis that AȾ migrates from the 
periphery and deposits in the brain with 
age and AD. González-MartÀnez et. al.(-
González-MartÀnez et al., 2011)  made a 
study in order to assess plasma AȾ1-Ͷ2 
and AȾ1-Ͷ0 levels in a blind study using 
pet dogs that were either successfully 
aging or ehibiting CDS (cognitive dys-function syndrome). The severity of co-
gnitive impairment was assessed using an 
owner-based uestionnaire. On average, 
young dogs presented significantly hig-
her plasma levels of AȾ1-Ͷ2 and AȾ1-Ͷ0 than aged, cognitively unimpaired dogs. Notably, among aged dogs, the levels of 
AȾ1-Ͷ2 and the AȾͶ2/Ͷ0 ratio were si-
gnificantly higher in those showing mild cognitive impairment than in either co-gnitively unimpaired or severely affected dogs. These results suggest that increa-
sed plasma AȾ1-Ͷ2 levels and AȾͶ2/Ͷ0 ratio could be a biomarker for canine co-
gnitive dysfunction, which is considered 
an ecellent natural model of early AD. 
Aside from the fibrillar AȾ found in di-ffuse plaques in AD, a smaller, more so-
luble and more toic form of AȾ Ȃ oligo-
meric AȾ Ȃ is also seen in the aged dog brain, that affects synaptic function and 
can even be found in plaues(Selkoe, 
2008). Similar to fibrillar AȾ, oligomeric 
AȾ can be measured in CSF, where levels are inversely related to levels in the brain (Head et al., 2010). 
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AȾ can also aggregate in the cerebral blood vessel walls and cause cerebrovas-
cular pathology (Prior et al., 199͸). This type of deposition is referred to as cere-
bral amyloid angiopathy (CAA). Typically 
CAA is composed of the shorter AȾ 1-Ͷ0 
peptide (Attems et al., 2005). Vascular AȾ may compromise the blood brain barrier, and can cause microhemorrhages via ve-
ssel wall viability (Deane and Zlokovic, 
2007). Much like humans, canines epe-
rience microhemorrhages with age. The-se cerebral hemorrhages are present in 
both animals with and without CAA, but 
are more common in those with the blo-
od vessel pathology (Uchida et al., 1991). 
Further, the distribution of CAA is similar 
in both species, with the occipital corte being predominantly susceptible.  
Moreover it is found that AȾ depositi-
on may lead to oidative damage or vice 
versa, oidative damage may lead to AȾ 
(Butterfield, 1997). Ultimately, oida-
tive damage accumulates with age and can lead to neuronal dysfunction and 
thus impact cognition(Butterfield et al., 
2001). Oidative damage occurs over time due to the overproduction of reacti-
ve oygen species (ROS) produced prima-
rily by mitochondria. ROS overproducti-
on may eceed the levels or production rate of endogenous antioidants and re-
sult in oidative damage to proteins, li-
pids, and nucleotides. Oidative damage can be measured by the amount of pro-
tein oidation (carbonyl groups), Ͷ-hy-
droynonenal, lipofuscin, lipofuscin-li-ke pigments, and malondialdehyde (lipid 
peroidation). Further, 8hydroy-2Ԣ-deo-
yguanosine (8OHdG) can be measured 
to detect DNA/RNA oidation. 
While oidative damage occurs with normal aging, it is more pronounced in 
AD (Lovell and Markesbery, 2008). In mitochondria isolated from aged canine brain, there is an increased production of 
ROS compared to mitochondria isolated 
from young animals. Canines also epe-rience an accumulation of carbonyl gro-
ups with age(Skoumalova et al., 2003). Li-
pid peroidation is ehibited in old dogs, 
measured by Ͷ-hydroynonenal (Papaio-
annou et al., 2001), lipofuscin (Rofina et 
al., 200͸), lipofuscin-like pigments(Papa-ioannou et al., 2001), or malondialdehy-
de (Head et al., 2002). Increased 8OHdG in aged canines has also been reported 
(Rofina et al., 200͸). In particular, incre-
ased protein oidation and lipid peroi-dation (lipofuscin-like pigment) correla-
tes with cognitive decline in dogs(Rofina et al., 2006).  
One hallmark AD pathology canines 
do not produce is neurofibrillary tangles 
(NFTs) (Russell et al., 1992). While no re-search to date has observed NFTs in the canine brain, the increased phosphoryla-tion seen at some sites of tau in AD cases also occurs in cognitively impaired cani-
nes (Pugliese et al., 200͸). This lack of NFT pathology could possibly be due to 
significant differences in the tau protein 
seuence between canines and humans. 
However, an advantage to dogs not accu-mulating NFTs is that they serve as a mo-
del that is selective for AȾ pathology and ideally suited for testing interventions 
that target this toic protein. Dogs initia-
lly develop plaues between the ages of 8 
and 9 years(Cotman and Head, 2008), a relatively young age, compared to many 
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non-human primate models with natu-
rally occurring AD-like pathology (Bons 
et al., 1992).  
CANINE MODELS /                      
PAS KAO MODELThe canine model has a rich literature in psychological and neurobiological re-
search, dating back to the 1800s. Canines are useful for aging research, have mode-rate lifespans of 12 to 20 years, depen-
ding on the breed (Brizzee, 1978, Mosier, 
1989), and are easy to handle due to a 
long history of domestication (Cummin-
gs et al., 199͸). Furthermore, canines are highly motivated to perform consisten-tly on cognitive tests using simple food 
rewards, making food deprivation para-digms unnecessary. In contrast, mice are not readily cooperative in performing be-havioral tasks, so physiological stressors 
including food restriction, water depri-
vation and immersion in water are often 
used (Blizard et al., 2003). Therefore me-asures of cognition may be engaging ot-her processes involved in stress respon-se, confounding performance scores. Im-portantly, the cognitive decline and pro-gressive age-associated neuropathology observed in dogs parallels that of hu-mans. The dog model provides a comple-
mentary system in which to test various theories of aging and to develop thera-
peutics when used in combination with 
other models. Osella et. al. (Osella et al., 
2007)  conducted a study which had two 
purposes. The first purpose of the study 
was to investigate the prevalence of cli-
nical signs of CDS in a general populati-
on of aged dogs. The second aim was to evaluate the use of a neuroprotective nu-
traceutical (Senilife1, Innovet Italia srl, 
Rubano, Italy) using an open-label clini-
cal pilot trial. Dogs were recruited from a geriatric population not referred for be-havioral consultations. A questionnaire 
with a checklist of behaviors was filled out to evaluate behavioral items grouped 
in the following categories: disorientati-on (D), socio-environmental interaction 
(I), sleepȂwake cycles (S), house soiling 
(H), general activity (A)Ȅ(DISHA). Each 
owner was asked to rate the freuency 
of the behavioral signs: never, rarely, of-
ten, or always. One hundred and twen-
ty-four dogs were assessed in the first 
surveyǢ 22 of the 12Ͷ dogs tested in the 
survey were ruled out based on eclusi-
on criteria (clinically and/or sensory se-vere impairment), 42 dogs had alterati-ons in one category and 33 dogs had si-
gns in 2 or more categories. Conseuen-
tly 75 dogs had signs consistent with 
CDS. Among this population eight dogs 
affected by CDS were enrolled for the se-
cond step of the project, an open-label cli-
nical pilot trial with the neuroprotective 
nutraceutical Senilife1. Senilife1 contains 
25 mg phosphatidylserine, 50 mg of stan-
dardized Ginkgo biloba etract, 33.5 mg/
d-alpha tocopherol and 20.5 mg pyridoi-ne per capsule and is dosed at one cap-
sule per 5 kg body weight. The investiga-
tor asked the owners to rate the freuen-
cy of behaviours referring to DISHA using a four point frequency scale (never, ra-
rely, often, always). Post-treatment, the 
owners were asked to evaluate all the si-
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gns in each category on a five point sca-le (much better, slightly better, the same, 
slightly worse, much worse). At the time 
of the first visit (V0) the owners were 
briefed verbally about the procedureǢ no 
behavioral advice was given throughout 
the study time and whenever appropria-
te therapy with Senilife1 (was started. At 
V0, V1 (28 3 days), V2 (5͸  3 days) and V3 
(8Ͷ 3 days) a control visit was performed 
and the owners were interviewed. Dogs 
treated with Senilife1 showed a highly 
significant difference at V3 compared to 
V0 ( p δ 0.001). Preliminary results from 
dogs on Senilife1 showed a marked im-
provement of CDS related signs, even if 
the dogs failed to show a complete remis-sion of symptoms. 
However, the use of dogs in aging studies provides some unique advanta-ges, as dogs may share a common envi-
ronment (including diet) with humans. Dogs also offer additional predictive va-
lidity when translating results to human clinical trials, as they absorb pharmace-
uticals with similar if not identical phar-
macokinetics. For eample, due to simila-rities to humans in terms of responsive-ness, drug tolerance and metabolism, the dog can be considered to be a useful mo-del for chronic statin treatment(Alberts, 
1990, Gerson et al., 1989). Barone et. al. 
(Barone et al., 2012)  evaluated the effect 
of atorvastatin treatment (80 mg/day for 
1Ͷ.5 months) on Biliverdin reductase-A 
(BVR-A) in the parietal corte, cerebellum 
and liver of a well characterized pre-clini-cal model of AD, the aged beagle. They fo-
und that atorvastatin significantly increa-
sed BVR-A protein levels, phosphorylati-
on and activity only in parietal corte. Ad-
ditionally, they found significant negative 
correlations between BVR-A and oida-
tive stress indices, as well as discrimina-tion learning error scores. Furthermore, 
BVR-A up-regulation and post-translatio-
nal modifications significantly correlated 
with Ⱦ-secretase protein levels in the bra-
in, suggesting a possible role for BVR-A in 
AȾ formation. 
Further, an interesting new study su-ggests that in the process of domestica-
tion in dogs, genes associated with di-
gestion have been selected that allow dogs to thrive on a diet rich in starch un-
like wolves and more similar to humans 
(Aelsson et al., 2013), suggesting simi-lar dietary absorption of nutrients. Mi-
ddle aged beagles between 5 and 9 years 
are similar to humans between Ͷ0 and ͸0 
years and beagles over 9 years are simi-lar to humans over 66 years(Head, 2013). Head et.al. (Head et al., 2012)  used a ca-nine model of human aging and AD. Aged dogs naturally develop learning and me-
mory impairments, human-type AȾ de-
posits and oidative damage in the bra-
in. Thus, 9 aged beagles (98-115 mont-
hs) were treated with a medical food coc-
ktail containing  (1) an etract of turme-
ric containing 95Ψ curcuminoidsǢ (2) an 
etract of green tea containing 50Ψ epi-
gallocatechingallateǢ (3) Nacetyl cyste-
ineǢ (Ͷ) R-alpha lipoic acidǢ and (5) an 
etract of black pepper containing 95Ψ piperine. Nine similarly aged dogs served as placebo-treated controls. After 3 mon-ths of treatment, 13 dogs completed a va-riable distance landmark task used as a measure of spatial attention. As compa-
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red to placebo-treated animals, dogs re-ceiving the medical food cocktail had si-
gnificantly lower error scores (t(11)αͶ.3, 
pα0.001) and were more accurate across 
all distances (F(1,9)α20.7, pα0.001), sug-gesting an overall improvement in spatial attention. Measures of visual discrimina-
tion learning, eecutive function and spa-
tial memory, and levels of brain and CSF 
AȾ were unaffected by the cocktail. Tre-
atment with a medical food cocktail in aged beagles, as a model of human aging and AD, resulted in an improvement in spatial attention, but not in other measu-res of cognition. Interestingly, the num-ber of animals that stopped responding 
as the cognitive tests became more diffi-
cult was higher for controltreated dogs, suggesting a possible improvement in motivation level in treated animals. Neu-
robiological studies show no changes in 
either the etent of AȾ plaue accumula-tion or the biochemical measures of so-
luble and insoluble AȾ1-Ͷ0 and AȾ1-Ͷ2. 
Our results indicate that this medical 
food cocktail may be beneficial for impro-ving spatial attention and motivation de-
ficits associated with impaired cognition in aging and AD. This study included 18 
beagles from Ridglan Farms, Inc. the ages 
of the animals ranged from 98-115 mont-
hs (Meanα103.2 SDα5.3) or 8.2-9.͸ years. 
All dogs were given a series of baseline tests and ranked on the basis of error sco-
res. Animals were given tests to measure spatial attention (landmark discriminati-on learning), spatial memory (3-choice), oddity learning, discrimination learning and reversal learning. 
Moreover, Heath S. (Heath et al., 2007) hypothesized that nutritional supplemen-tation can be used in the management of 
the condition and their trial was designed to investigate the therapeutic effects of a 
specific supplement when compared to a 
placebo. The trial was conducted in a cli-
nical contet and involved 20 UK veteri-nary practices, giving geographical spre-ad across the country. The duration of the 
trial was 5͸ days, including a baseline pe-
riod of 7 days and a post-trial period of 
7 days. There was a significant difference 
between the treated and the placebo gro-ups in relation to improvement in their scores for disorientation, changes in inte-raction and house soiling behavior at day 21, day 28 and day 42. These results su-pport the clinical practice of nutritional supplementation as a valuable  compo-nent of the therapeutic approach in cases of canine cognitive dysfunction 

	ȃ
FUNCTIONS / KOGNITIVNI 
	ǧ	
Cognitive testing procedures for ca-
nines were initially developed by modi-fying nonhuman primate cognitive tests 
(Milgram et al., 199Ͷ). A variety of tests have been developed to assess cognitive function in various domains and corres-ponding brain localization in dogs.  The-re are cognitive domains assessed in dog 
aging and how they compare with asse-ssment tasks for non-human primate and humans. Many of these tests are analogo-us to cognitive tests used for nonhuman primates and humans. As in humans, ca-nine individual variability and doma-
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in-specific cognitive vulnerabilities are 
key features of decline with age (Milgram 
et al., 199Ͷ). Beginning in middle age, in-dividual variability in cognitive scores 
begins to increase, with the largest va-riability seen in aged dogs (Adams et al., 2000). Additionally, vulnerability to dec-
line with age varies as a function of cogni-tive domain and the cortical circuits en-
gaged. For eample, size discrimination 
learning is sensitive to age, while simple 
object discrimination is not (Head et al., 
1995), similar to monkey models of aging 
(Rapp, 1990). Further, prefrontal depen-dent reversal learning is more age sensi-tive than discrimination learning (Adams et al., 2000). There are several measures of co-gnition that are age-sensitive and tre-atment-sensitive in dogs that can be used as intervention outcome measures to as-
sess different cognitive abilities with ana-logous tasks in non-human primates and in humans. Much like humans, the aging 
canine shows cognitive decline with va-rious cognitive domains and cortical pat-
hways being differentially affected (Mi-
lgram et al., 199Ͷ). Dogs show cogniti-
ve deficits due to age in tests measuring 
comple learning, eecutive function, spatial learning and attention, and me-
mory (Studzinski et al., 200͸). In additi-on to cognitive domain variability, indivi-
dual dogs also show variability in cogniti-ve function as seen in humans (Adams et al., 2000). This variability becomes most apparent in old canines, and using spa-
tial learning and memory tasks, we are able to distinguish three groups of varia-
bility: (1) successful agers, (2) impaired 
dogs whose scores fell two SD above the mean of the young animals, and (3) seve-
rely impaired dogs who failed to learn the task (Head et al., 2001). The availability of agematched animals with and witho-
ut cognitive deficits allowed researchers 
to determine which types of neuropat-hology contribute to individual cognitive impairments in these animals.  
Several tasks, similar to those used for testing cognition in non-human prima-tes, have been developed to measure co-gnitive decline in the aging canine (Mil-
gram et al., 2002). Such tasks include lan-dmark discrimination, oddity discrimina-
tion, object, size and black/white discri-mination and reversal tasks, and a spatial memory task. All testing occurs in a mo-
dified Wisconsin General Testing Appara-tus such that the motor and sensory de-mands are consistent across tasks. The landmark discrimination task, measures visuospatial function and allo-centric learning. The oddity discrimina-
tion task measures comple learning, as 
well as prefrontal corte function. Aged 
dogs show deficits in oddity discrimina-
tion learning (Cotman et al., 2002). Tests 
of object, size and black/white discrimi-nation are administered to measure asso-
ciative learning ability. Eecutive functi-on can be evaluated immediately after discrimination learning has been com-
pleted by using the object, size or black/
white reversal objects. Memory also dec-
lines with age in dogs. The most useful age-sensitive task used is a spatial me-
mory task, in which dogs are reuired to recognize the location of a sample stimu-lus and then respond to a different locati-
on during the test trial (Head et al., 1995). 
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In addition to cognitive outcome measu-res, researchers and veterinarians are in-terested in measuring functional outco-mes. Further, laboratory-based cognitive testing as described above is labor inten-sive and requires many months to years 
to obtain data. An open field test can be used to observe the behavioral patterns of animals in an empty room for 10 min 
(Siwak et al., 2001). Measures of canine function can also 
be assessed in a clinical setting (Lands-
berg et al., 2012). Clinical measures have been developed consisting of pet dog 
owner based evaluation of dog behavio-
ral changes (Landsberg et al., 2012) simi-lar to those used in human clinical eva-luations, such as the mini mental sta-
te eam (MMSE), the MoCA and the CDR test. Although there are different versi-ons of these questionnaires, all appear to be sensitive to the presence of canine co-gnitive dysfunction. The evaluation con-
sists of items such as walking, posture/
emotion of epression, elimination be-
havior, life rhythm, play behavior, eplo-
ratory behavior, learned specific beha-vior, adaptive capabilities, and interacti-
ons with other animals or with owners. The items of individual questionnaires can be used to derive scores that distin-
guish between normally and pathologica-lly aging dogs. Adult and older dogs ge-
nerally score worse with these types of 
evaluation tools, and old dogs show indi-vidual variability in terms of the amount of cognitive dysfunction reported (Bosch et al., 2012). 
Salvine et. al. (2011) conducted a study, using data from a large crosssecti-
onal survey of older dogs (n α 957), whi-ch aimed to develop a clinical scale for as-
sessing CCD (Canine Cognitive Dysfun-ction). Data-driven analytical techniques 
were used to distil 27 significant behavi-
oral items (previously identified as rele-
vant to CCD) into an assessment tool with 
maimal cognito-behavioural breadth 
whilst maintaining clinical utility. The re-
sulting CCD rating scale (CCDR) compri-
sed 13 behavioral items, of which three 
were sensitive to the severity of the disea-
se stage. When tested on an independent 
survey sample, the CCDR had an overall 
98.9Ψ diagnostic accuracy with a 77.8Ψ 
positive predictive value and a 99.3Ψ ne-
gative predictive value. TestȂre-test relia-
bility of the CCDR over 2 months was also 
high (r α 0.73, P δ 0.0001). In conjuncti-
on with veterinary assessment, the CCDR could be a valuable tool in research and clinical settings for both the assessment and longitudinal tracking of cognitive change. It can distinguish those neurobe-
havioral changes associated with cogniti-ve dysfunction from normal ageing. 
Ȁ,The aged dog naturally develops dec-line in many different cognitive domains 
and ehibits human-like individual varia-bility in the aging process. The neurobi-ological basis for cognitive dysfunction may be related to structural changes that 
reflect degeneration. Data on the preva-
lence of CDS suggest that the phenome-non is underestimated in veterinary me-
dicine. CCD shares several similarities 
with human AD, such as the progressi-ve characteristics of the clinical syndro-
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me, neuropathological abnormalities and 
pharmacological responsiveness. CCD may therefore serve as a useful translati-onal model for AD. The canine model has numerous 
advantages, however, systematic cogni-tive testing can be a lengthy and costly 
process and reuires significant techni-
cal support. Still, the canine model should be considered as an option since it is less involved and costly than a human clinical 
prevention study. Successful studies of human diseases require an appropriate 
animal model. Overall, using the dog as a pre-clinical model for testing preventive approaches for AD may be a useful step 
that complements work in rodents and 
non-human primates. Canines are more 
suitable for eamining human disorders than mice, as canines have evolved phy-
siologically and genetically in close proi-mity to humans. Taken together, the aged dog may capture key features of human aging, making them particularly useful for studies of therapeutics that can be translated into human clinical trials. Al-though a canine model is ideal for hu-
man disease studies, to our knowledge, no such model has been reported to date, due to the lack of canine embryonic stem 
cells, which are generally used for gene targeting, and proper protocols for pro-ducing mature oocytes in vitro.  Further, prevention studies could be accomplished to test the effects of an in-tervention on the development of cogniti-ve decline and neuropathology. 
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